{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:00:13Z","timestamp":1792278013746,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical Science Research Project of Hebei","award":["20260081"],"award-info":[{"award-number":["20260081"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07958-4","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:53:19Z","timestamp":1789703599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue"],"prefix":"10.1007","author":[{"given":"Xinning","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"22","key":"7958_CR1","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1097\/CM9.0000000000002906","volume":"136","author":"Z Hu","year":"2023","unstructured":"Hu Z, Ding L, Yao Y. Atrial fibrillation: mechanism and clinical management. Chin Med J. 2023;136(22):2668\u201376.","journal-title":"Chin Med J"},{"key":"7958_CR2","doi-asserted-by":"crossref","unstructured":"Sagris M, Vardas EP, Theofilis P, Antonopoulos AS, Oikonomou E, Tousoulis D. Atrial fibrillation: pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 2021;23(1).","DOI":"10.3390\/ijms23010006"},{"issue":"13","key":"7958_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2019.0693","volume":"321","author":"DL Packer","year":"2019","unstructured":"Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261\u201374.","journal-title":"JAMA"},{"key":"7958_CR4","doi-asserted-by":"publisher","first-page":"1369594","DOI":"10.3389\/fnut.2024.1369594","volume":"11","author":"Z Gao","year":"2024","unstructured":"Gao Z, Wei H, Xiao J, Huang W. Mediators between body mass index and atrial fibrillation: a Mendelian randomization study. Front Nutr. 2024;11:1369594.","journal-title":"Front Nutr"},{"issue":"1","key":"7958_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12933-023-01913-5","volume":"22","author":"H Shu","year":"2023","unstructured":"Shu H, Cheng J, Li N, Zhang Z, Nie J, Peng Y, et al. Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance. Cardiovasc Diabetol. 2023;22(1):192.","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"7958_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1161\/CIRCULATIONAHA.120.045864","volume":"141","author":"CB Granger","year":"2020","unstructured":"Granger CB, Mahaffey KW. Preventing atrial fibrillation with treatments for diabetes mellitus. Circulation. 2020;141(15):1235\u20137.","journal-title":"Circulation"},{"issue":"8","key":"7958_CR7","first-page":"1201","volume":"24","author":"AL Poggi","year":"2022","unstructured":"Poggi AL, Gaborit B, Schindler TH, Liberale L, Montecucco F, Carbone F. Epicardial fat and atrial fibrillation: the perils of atrial failure. Europace: Eur pacing Arrhythm cardiac Electrophysiol : J working groups cardiac pacing Arrhythm cardiac Cell Electrophysiol Eur Soc Cardiol. 2022;24(8):1201\u201312.","journal-title":"Europace: Eur pacing Arrhythm cardiac Electrophysiol : J working groups cardiac pacing Arrhythm cardiac Cell Electrophysiol Eur Soc Cardiol"},{"key":"7958_CR8","doi-asserted-by":"crossref","unstructured":"Sanusi M, Vempati R, Umashankar D, Tarannum S, Varma Y, Mohammed F, et al. Molecular mechanisms of atrial fibrillation recurrence after successful catheter ablation. Cells. 2025;15(1).","DOI":"10.3390\/cells15010036"},{"issue":"9","key":"7958_CR9","doi-asserted-by":"publisher","first-page":"e13277","DOI":"10.1111\/obr.13277","volume":"22","author":"M Couselo-Seijas","year":"2021","unstructured":"Couselo-Seijas M, Rodr\u00edguez-Ma\u00f1ero M, Gonz\u00e1lez-Juanatey JR, Eiras S. Updates on epicardial adipose tissue mechanisms on atrial fibrillation. Obes Rev Off J Int Association Study Obes. 2021;22(9):e13277.","journal-title":"Obes Rev Off J Int Association Study Obes"},{"key":"7958_CR10","doi-asserted-by":"crossref","unstructured":"Hammache N, Pegorer-Sfes H, Benali K, Magnin Poull I, Olivier A, Echivard M, et al. Is there an association between epicardial adipose tissue and outcomes after paroxysmal atrial fibrillation catheter ablation? J Clin Med. 2021;10(14).","DOI":"10.3390\/jcm10143037"},{"key":"7958_CR11","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.","journal-title":"Mol Metab"},{"issue":"11","key":"7958_CR12","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873\u201388.","journal-title":"Diabetes Care"},{"key":"7958_CR13","doi-asserted-by":"publisher","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209.","journal-title":"Front Immunol"},{"issue":"7","key":"7958_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Reviews Cardiol. 2023;20(7):463\u201374.","journal-title":"Nat Reviews Cardiol"},{"issue":"7","key":"7958_CR15","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/dom.14700","volume":"24","author":"S Verma","year":"2022","unstructured":"Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022;24(7):1288\u201399.","journal-title":"Diabetes Obes Metab"},{"key":"7958_CR16","doi-asserted-by":"publisher","first-page":"5578216","DOI":"10.1155\/2021\/5578216","volume":"2021","author":"N Zhao","year":"2021","unstructured":"Zhao N, Wang X, Wang Y, Yao J, Shi C, Du J, et al. The effect of liraglutide on epicardial adipose tissue in type 2 diabetes. J Diabetes Res. 2021;2021:5578216.","journal-title":"J Diabetes Res"},{"issue":"9","key":"7958_CR17","first-page":"e46153","volume":"15","author":"S Zain","year":"2023","unstructured":"Zain S, Shamshad T, Kabir A, Khan AA. Epicardial adipose tissue and development of atrial fibrillation (AFIB) and heart failure with preserved ejection fraction (HFpEF). Cureus. 2023;15(9):e46153.","journal-title":"Cureus"},{"key":"7958_CR18","doi-asserted-by":"publisher","first-page":"112317","DOI":"10.1016\/j.jep.2019.112317","volume":"248","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Chen B, Chen X, Wang Y, Ji J, Kizaibek M, et al. Arnebiae Radix prevents atrial fibrillation in rats by ameliorating atrial remodeling and cardiac function. J Ethnopharmacol. 2020;248:112317.","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"7958_CR19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacbts.2023.01.005","volume":"8","author":"LJ Bohne","year":"2023","unstructured":"Bohne LJ, Jansen HJ, Dorey TW, Daniel IM, Jamieson KL, Belke DD, et al. Glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice. JACC Basic Translational Sci. 2023;8(8):922\u201336.","journal-title":"JACC Basic Translational Sci"},{"issue":"3","key":"7958_CR20","doi-asserted-by":"publisher","first-page":"e011155","DOI":"10.1161\/JAHA.118.011155","volume":"8","author":"H Dai","year":"2019","unstructured":"Dai H, Yuan Y, Yin S, Zhang Y, Han Y, Sun L, et al. Metoprolol inhibits profibrotic remodeling of epicardial adipose tissue in a canine model of chronic obstructive sleep apnea. J Am Heart Association. 2019;8(3):e011155.","journal-title":"J Am Heart Association"},{"key":"7958_CR21","doi-asserted-by":"publisher","first-page":"120422","DOI":"10.1016\/j.lfs.2022.120422","volume":"297","author":"BU Jack","year":"2022","unstructured":"Jack BU, Mamushi M, Viraragavan A, Dias S, Pheiffer C. Comparing the effects of tumor necrosis factor alpha, lipopolysaccharide and palmitic acid on lipid metabolism and inflammation in murine 3T3-L1 adipocytes. Life Sci. 2022;297:120422.","journal-title":"Life Sci"},{"key":"7958_CR22","doi-asserted-by":"publisher","first-page":"109252","DOI":"10.1016\/j.cbi.2020.109252","volume":"332","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian J, Diao S, Zhang G, Xiao M, Chang D. GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1\u03b2-induced metabolic disturbance and mitochondrial dysfunction. Chemico-Biol Interact. 2020;332:109252.","journal-title":"Chemico-Biol Interact"},{"issue":"14","key":"7958_CR23","doi-asserted-by":"publisher","first-page":"7751","DOI":"10.1111\/jcmm.15407","volume":"24","author":"B Li","year":"2020","unstructured":"Li B, Po SS, Zhang B, Bai F, Li J, Qin F, et al. Metformin regulates adiponectin signalling in epicardial adipose tissue and reduces atrial fibrillation vulnerability. J Cell Mol Med. 2020;24(14):7751\u201366.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"7958_CR24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jacbts.2023.03.022","volume":"8","author":"L Stoll","year":"2023","unstructured":"Stoll L, Lo JC. GLP-1 Receptor agonists, the holy grail preventing atrial fibrillation in patients with T2D? JACC Basic Translational Sci. 2023;8(8):937\u20138.","journal-title":"JACC Basic Translational Sci"},{"key":"7958_CR25","doi-asserted-by":"crossref","unstructured":"Chan CS, Lin FJ, Chen YC, Lin YK, Higa S, Chen SA et al. Glucagon-like peptide-1 receptor activation reduces pulmonary vein arrhythmogenesis and regulates calcium homeostasis. Int J Mol Sci. 2023;24(17).","DOI":"10.3390\/ijms241713100"},{"key":"7958_CR26","doi-asserted-by":"crossref","unstructured":"Goldberger JJ, Mitrani RD, Fishman J, Zaatari G, Lowery M, Baez-Garcia C, et al. The liraglutide effects in atrial fibrillation (LEAF) study. JACC Clin Electrophysiol. 2026.","DOI":"10.1016\/j.jacep.2026.03.026"},{"key":"7958_CR27","doi-asserted-by":"publisher","first-page":"156678","DOI":"10.1016\/j.metabol.2026.156678","volume":"182","author":"Y Fan","year":"2026","unstructured":"Fan Y, Chen X, Cai X, Dong Y, Liu C, Chen Y, et al. SGLT2 inhibitors and GLP-1 receptor agonists in atrial fibrillation treatment: clinical evidence and mechanistic insights. Metab Clin Exp. 2026;182:156678.","journal-title":"Metab Clin Exp"},{"key":"7958_CR28","doi-asserted-by":"crossref","unstructured":"Karakasis P, Fragakis N, Patoulias D, Theofilis P, Sagris M, Koufakis T, et al. The emerging role of glucagon-like peptide-1 receptor agonists in the management of obesity-related heart failure with preserved ejection fraction: benefits beyond what scales can measure? Biomedicines. 2024;12(9).","DOI":"10.3390\/biomedicines12092112"},{"key":"7958_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pcad.2023.04.010","volume":"78","author":"ME Middeldorp","year":"2023","unstructured":"Middeldorp ME, Kamsani SH, Sanders P. Obesity and atrial fibrillation: prevalence, pathogenesis, and prognosis. Prog Cardiovasc Dis. 2023;78:34\u201342.","journal-title":"Prog Cardiovasc Dis"},{"key":"7958_CR30","doi-asserted-by":"crossref","unstructured":"Ma M, Zhi H, Yang S, Yu EY, Wang L. Body mass index and the risk of atrial fibrillation: a mendelian randomization study. Nutrients. 2022;14(9).","DOI":"10.3390\/nu14091878"},{"issue":"1","key":"7958_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12916-022-02413-1","volume":"20","author":"M Zhao","year":"2022","unstructured":"Zhao M, Song L, Zhao Q, Chen Y, Li B, Xie Z, et al. Elevated levels of body mass index and waist circumference, but not high variability, are associated with an increased risk of atrial fibrillation. BMC Med. 2022;20(1):215.","journal-title":"BMC Med"},{"key":"7958_CR32","doi-asserted-by":"publisher","first-page":"932262","DOI":"10.3389\/fcvm.2022.932262","volume":"9","author":"M Conte","year":"2022","unstructured":"Conte M, Petraglia L, Cabaro S, Valerio V, Poggio P, Pilato E, et al. Epicardial adipose tissue and cardiac arrhythmias: focus on atrial fibrillation. Front Cardiovasc Med. 2022;9:932262.","journal-title":"Front Cardiovasc Med"},{"key":"7958_CR33","doi-asserted-by":"crossref","unstructured":"Anagnostopoulos I, Kousta M, Kossyvakis C, Paraskevaidis NT, Vrachatis D, Deftereos S, et al. Epicardial adipose tissue and atrial fibrillation recurrence following catheter ablation: a systematic review and meta-analysis. J Clin Med. 2023;12(19).","DOI":"10.3390\/jcm12196369"},{"issue":"4","key":"7958_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14779072.2022.2067144","volume":"20","author":"JP Scarano Pereira","year":"2022","unstructured":"Scarano Pereira JP, Owen E, Martinino A, Akmal K, Abouelazayem M, Graham Y, et al. Epicardial adipose tissue, obesity, and the occurrence of atrial fibrillation: an overview of pathophysiology and treatment methods. Expert Rev Cardiovasc Ther. 2022;20(4):307\u201322.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"8","key":"7958_CR35","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050\u201368.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"7958_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","volume":"34","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri N, Charlton M, Gray M, Noureddin M. The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists. Expert Opin Investig Drugs. 2025;34(3):169\u201395.","journal-title":"Expert Opin Investig Drugs"},{"key":"7958_CR37","doi-asserted-by":"crossref","unstructured":"Diz-Chaves Y, Mastoor Z, Spuch C, Gonz\u00e1lez-Mat\u00edas LC, Mallo F. Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases. Int J Mole Sci. 2022;23(17).","DOI":"10.3390\/ijms23179583"},{"issue":"12","key":"7958_CR38","doi-asserted-by":"publisher","first-page":"e14292","DOI":"10.1111\/eci.14292","volume":"54","author":"A Saglietto","year":"2024","unstructured":"Saglietto A, Falasconi G, Penela D, Francia P, Sau A, Ng FS, et al. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis. Eur J Clin Invest. 2024;54(12):e14292.","journal-title":"Eur J Clin Invest"},{"key":"7958_CR39","doi-asserted-by":"crossref","unstructured":"Cesaro A, Pastori D, Acerbo V, Biccir\u00e8 FG, Golino M, Panico D, et al. Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials. Eur J Prev Cardiol. 2025.","DOI":"10.1093\/eurjpc\/zwaf257"},{"issue":"6","key":"7958_CR40","doi-asserted-by":"publisher","first-page":"103067","DOI":"10.1016\/j.dsx.2024.103067","volume":"18","author":"HD Zhang","year":"2024","unstructured":"Zhang HD, Ding L, Liu K, Mi LJ, Zhang AK, Yu FY, et al. Semaglutide for the prevention of atrial fibrillation: a systematic review and meta-analysis. Diabetes Metabolic Syndrome. 2024;18(6):103067.","journal-title":"Diabetes Metabolic Syndrome"},{"issue":"8","key":"7958_CR41","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00380-018-01327-4","volume":"34","author":"H Nakamura","year":"2019","unstructured":"Nakamura H, Niwano S, Niwano H, Fukaya H, Murakami M, Kishihara J, et al. Liraglutide suppresses atrial electrophysiological changes. Heart Vessels. 2019;34(8):1389\u201393.","journal-title":"Heart Vessels"},{"issue":"9","key":"7958_CR42","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","volume":"117","author":"C Withaar","year":"2021","unstructured":"Withaar C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, Sillj\u00e9 HHW, Schouten EM, et al. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovascular Res. 2021;117(9):2108\u201324.","journal-title":"Cardiovascular Res"},{"key":"7958_CR43","doi-asserted-by":"crossref","unstructured":"Masson W, Lavalle-Cobo A, Nogueira JP. Effect of SGLT2-inhibitors on epicardial adipose tissue: a meta-analysis. Cells. 2021;10(8).","DOI":"10.3390\/cells10082150"},{"issue":"4","key":"7958_CR44","doi-asserted-by":"publisher","first-page":"bvz042","DOI":"10.1210\/jendso\/bvz042","volume":"4","author":"G Iacobellis","year":"2020","unstructured":"Iacobellis G, Villasante Fricke AC. Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity. J Endocr Soc. 2020;4(4):bvz042.","journal-title":"J Endocr Soc"},{"key":"7958_CR45","doi-asserted-by":"crossref","unstructured":"D\u2019Marco L, Puchades MJ, Gorriz JL, Romero-Parra M, Lima-Mart\u00ednez M, Soto C, et al. Epicardial adipose tissue, adiponectin and leptin: a potential source of cardiovascular risk in chronic kidney disease. Int J Mole Sci. 2020;21(3).","DOI":"10.3390\/ijms21030978"},{"key":"7958_CR46","doi-asserted-by":"crossref","unstructured":"Guo Y, Liu L, Wang J. Adiponectin and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies. Biosci Rep. 2019;39(6).","DOI":"10.1042\/BSR20182284"},{"issue":"1","key":"7958_CR47","first-page":"63","volume":"75","author":"A AlKassas","year":"2023","unstructured":"AlKassas A, Fouda M, Fassini G, Sanhoury M. Pre-procedural high serum visfatin and tumor necrosis factor-\u03b1 might predict recurrent atrial fibrillation after catheter ablation. Egypt Heart J: (EHJ) : Off Bull Egypt Soc Cardiol. 2023;75(1):63.","journal-title":"Egypt Heart J: (EHJ) : Off Bull Egypt Soc Cardiol"},{"issue":"2","key":"7958_CR48","doi-asserted-by":"publisher","first-page":"103726","DOI":"10.1016\/j.numecd.2024.08.019","volume":"35","author":"G Iacobellis","year":"2025","unstructured":"Iacobellis G, Goldberger JJ, Lamelas J, Martinez CA, Sterling CM, Bodenstab M, et al. Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control. Nutr Metabolism Cardiovasc Diseases: NMCD. 2025;35(2):103726.","journal-title":"Nutr Metabolism Cardiovasc Diseases: NMCD"},{"issue":"3","key":"7958_CR49","doi-asserted-by":"publisher","first-page":"101535","DOI":"10.1016\/j.diabet.2024.101535","volume":"50","author":"L Duvillard","year":"2024","unstructured":"Duvillard L, Pais de Barros JP, Rouland A, Simoneau I, Denimal D, Bouillet B, et al. No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes. Diabetes Metab. 2024;50(3):101535.","journal-title":"Diabetes Metab"},{"issue":"2","key":"7958_CR50","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12020-019-01891-3","volume":"64","author":"A Singh","year":"2019","unstructured":"Singh A, Fernandes JRD, Chhabra G, Krishna A, Banerjee A. Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice. Endocrine. 2019;64(2):349\u201366.","journal-title":"Endocrine"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07958-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:53:24Z","timestamp":1789703604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07958-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":50,"alternative-id":["7958"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07958-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal study protocol was approved by the Ethics Committee of Hebei Provincial People\u2019s Hospital [2025-DW-142]. All experiments were conducted in strict accordance with the National Research Council\u2019s Guide for the Care and Use of Laboratory Animals and reported following the ARRIVE guidelines.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No generative AI or AI-assisted technolog were used in the development of this manuscript. The authors assume full responsibility for all content.","order":3,"name":"Ethics","label":"Generative AI","group":{"name":"EthicsHeading","label":"Declarations"}}]}}